ALT-836

Altor BioScience · Phase 2 active Small molecule

At a glance

Generic name	ALT-836
Also known as	Formerly TNX-832; Sunol-cH36
Sponsor	Altor BioScience
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome (PHASE1)
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors (PHASE1)
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ALT-836 CI brief — competitive landscape report
ALT-836 updates RSS · CI watch RSS
Altor BioScience portfolio CI